CBD items and other cannabis derivatives are getting more and more popular because people seek those as potential treatment options for pain. That also applies to the kind of pain that occurs due to chronic illness. Anyhow, it may not be clear whether the goods advertised as having Delta-9-THC or cannabidiol as an ingredient contains it, suggested a recent study.
People buy products thinking that those are devoid of THC, but they may contain much THC, said one of the study authors named Jodi Gilman. For your information, Gilman works as an investigator at the Massachusetts General Hospital Department of Psychiatry’s Center for Addiction Medicine. A patient consumed an item she felt was a CBD-only product, and then she experienced intoxication, disorientation, and fear when driving back home on the same day, said Gilman.
Cannabidiol cannot cause any of those effects. At least, research is yet to prove that CBD can cause the same. Even full spectrum hemp products are unlikely to cause those issues.
Grown-ups who wished to utilize cannabis and the plant-related goods for insomnia, depression, or pain went through some interviews. At the same time, those adults also offered urine samples. The interviewers asked them whether the items they were consuming were CBD-dominant, THC-dominant, or a blend of both. The researchers concerned checked the samples for cannabidiol and tetrahydrocannabinol metabolites.
Up to 97 study participants, with an average age of about 40 years, offered around 260 urine samples. Over half of them said that they were consuming products rarely, less than one time per month. They said that their utilization of products went up over time.
There was at least a single cannabis metabolite in 220 urine samples. Surprisingly, around 30% of the cannabidiol-dominant product user samples lacked detectable metabolites of cannabidiol. The same applied to 37% of the items of those participants with THC and cannabidiol in equal parts. There was detectable THC in around 78% of the samples of the cannabidiol-dominant group. Meanwhile, of the THC-dominant product user samples, around 10% lacked detectable metabolites of tetrahydrocannabinol. The same applied to around 35% of the items with equal amounts of cannabidiol and tetrahydrocannabinol.
There are still many questions regarding what the products contain, plus what effects those have on users, said Gilman.